Naila Rabbani
Executive Director
Professor Naila Rabbani received her BSc Biological & Medicinal Chemistry in 1998 and PhD Biochemistry in 2002 from University of Essex, Colchester, U.K. She was Reader in Medical Systems Biology, Warwick Medical School, University of Warwick, Coventry, UK, and then Professor of Basic Medical Sciences, College of Medicine, Doha, Qatar. She is a leading international scientist and a key figure in the field of biomedical research and diagnostics with over 25 years’ experience in clinical translational research. She is a leading international expert in protein glycation research in which she developed the AGEomics technology and pioneered the application of artificial intelligence (AI) machine learning for the development of diagnostic algorithms with protein glycation biomarkers as features. Her distinguished career is dedicated to bridging the gap between fundamental biomedical research and the development of practical clinical tools that improve lives.
Professor Rabbani’s expertise is not confined to the laboratory. She is a pioneer in translational medicine, specializing in the discovery and validation of biomarkers. Her work has been instrumental in identifying specific biochemical markers that enable early detection and accurate prognosis.
Her contributions are directly aligned with the mission of iDiagnostix, where her scientific leadership helps drive the innovation of next-generation diagnostic solutions. Professor Rabbani’s research provides the robust scientific foundation for developing tests that are not only highly accurate but also clinically actionable, ultimately aiming to transform healthcare outcomes.
She has 333 publications (163 peer reviewed papers and 171 conference abstracts and papers) with over 19,510 citations; h-index 77 (Google Scholar). By h-index, she is in the top 2% of scientists globally (AD Scientific Index).
Some recent papers
Some recent papers
- Naila Rabbani and Paul J Thornalley (2021) Protein glycation – emerging evidence as biomarkers of metabolic dysfunction and early-stage decline in health in the era of precision medicine. Redox Biology 42, 101920
- Naila Rabbani (2022) Methylglyoxal and glyoxalase 1 – a metabolic stress pathway linking hyperglycemia to the unfolded protein response and vascular complications of diabetes Clinical Science 136, 19–824.
- Naila Rabbani (2022) AGEomics biomarkers and machine learning – realising the potential of protein glycation in clinical diagnostics. International Journal of Molecular Science Sci. 23, 4584
- Al-Saei, A.N.J.M., Eldine, W.N., Rajpoot, K., Arshad, N., Al-Shammari, A.R., Kamal, M., Al-Shabeeb Akil, A., Fakhro, K.A., Thornalley, P.J. and Rabbani, N. (2023) Validation of plasma protein glycation and oxidation biomarkers for the diagnosis of autism. Molecular Psychiatry 29, 653 – 659.
- Xue, M., Rabbani, N. and Thornalley, P.J. (2024) Increased cellular protein modification by methylglyoxal activates three sensors of the unfolded protein response. Redox Biol. 65, 103025.
- Rabbani, N. and Thornalley, P.J. (2024) Hexokinase-linked glycolytic overload and unscheduled glycolysis in hyperglycemia-induced pathogenesis in insulin resistance, beta-cell glucotoxicity and diabetic vascular complications. Frontiers in Endocrinology 14, 268308.
- Rabbani, N. and Thornalley, P.J. (2024) Hexokinase-linked glycolytic overload and unscheduled glycolysis in hyperglycemia-induced pathogenesis in insulin resistance, beta-cell glucotoxicity and diabetic vascular complications. Frontiers in Endocrinology 14, 1268303
- Rabbani, N. and Thornalley, P.J. (2024) Unravelling the impaired incretin effect in obesity and type 2 diabetes: key role of hyperglycemia-induced unscheduled glycolysis and glycolytic overload. Diabetes Res. Clin. Pract., 217, 111905